Tarsus Pharmaceuticals, Inc. cotiza a 73.16 USD y tiene una capitalización bursátil de $3.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demod…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.43 | $-0.16 | $-0.20 |
| Estimado | $-1.77 | $-0.20 | $-0.42 | $0.01 |
| Sorpresa | — | -115.0% | +61.9% | -2100.0% |
| Métrica | TARS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -15.7% | -38.6% | +22.9% |
| Net Margin | -14.7% | -33.6% | +18.8% |
| FCF Margin | -4.9% | -13.9% | +8.9% |
| ROE | -19.3% | -40.4% | +21.1% |
| ROA | -11.8% | -32.0% | +20.2% |
| Current Ratio | 3.85 | 2.84 | +1.01 |
| Debt / Equity | 0.21 | 0.28 | -0.07 |